Eupraxia Pharmaceuticals Inc (TO:EPRX) — Stock Price
Eupraxia Pharmaceuticals Inc (TO:EPRX) is currently trading at CA$9.37 CAD, down 0.95% today. Over the past 52 weeks, shares have ranged between CA$6.94 and CA$12.50. This page tracks Eupraxia Pharmaceuticals Inc's live share price on the TO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see EPRX stock market capitalisation.
Eupraxia Pharmaceuticals Inc (EPRX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Eupraxia Pharmaceuticals Inc's daily closing share price and trading volume on the TO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Eupraxia Pharmaceuticals Inc Income Statement — Revenue, Profit & Earnings by Year
Eupraxia Pharmaceuticals Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | CA$0.00 | CA$0.00 | CA$0.00 | CA$0.00 | CA$0.00 |
| Cost of Revenue | CA$235.25K | CA$209.91K | CA$193.27K | CA$111.53K | CA$116.81K |
| Gross Profit | CA$-235.25K | CA$-209.91K | CA$-193.27K | CA$-111.53K | CA$-116.81K |
| Research & Development | CA$21.83 Million | CA$27.54 Million | CA$17.20 Million | CA$9.68 Million | CA$859.78K |
| SG&A | CA$15.71 Million | CA$9.65 Million | CA$5.81 Million | CA$8.89 Million | CA$1.27 Million |
| Total Operating Expenses | CA$36.76 Million | CA$37.92 Million | CA$23.20 Million | CA$18.68 Million | CA$2.25 Million |
| Operating Income | CA$-36.99 Million | CA$-36.90 Million | CA$-22.63 Million | CA$-20.87 Million | CA$-2.25 Million |
| EBITDA | CA$-33.72 Million | CA$-37.40 Million | CA$-22.14 Million | CA$-21.96 Million | CA$-2.01 Million |
| EBIT | CA$-33.95 Million | CA$-37.61 Million | CA$-22.33 Million | CA$-22.07 Million | CA$-2.13 Million |
| Interest Expense | CA$1.31 Million | CA$1.58 Million | CA$1.59 Million | CA$1.30 Million | CA$1.88 Million |
| Income Before Tax | CA$-35.27 Million | CA$-39.18 Million | CA$-23.92 Million | CA$-23.37 Million | CA$-4.01 Million |
| Income Tax Expense | CA$2.47K | CA$-89.67K | CA$930.52K | CA$-1.34 Million | CA$1.87 Million |
| Net Income | CA$-34.94 Million | CA$-37.39 Million | CA$-23.26 Million | CA$-22.99 Million | CA$-4.00 Million |
Eupraxia Pharmaceuticals Inc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Eupraxia Pharmaceuticals Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | CA$50.24 Million | CA$26.72 Million | CA$25.88 Million | CA$31.22 Million | CA$1.45 Million |
| Total Current Assets | CA$34.44 Million | CA$19.80 Million | CA$25.18 Million | CA$30.60 Million | CA$1.14 Million |
| Cash & Equivalents | — | CA$0.00 | CA$7.43 Million | — | — |
| Short-term Investments | — | CA$-6.16 Million | CA$0.00 | CA$9.01 Million | CA$0.00 |
| Net Receivables | CA$228.87K | CA$251.34K | CA$121.51K | CA$337.03K | CA$620.61K |
| Inventory | — | CA$1.00 | — | — | — |
| Property, Plant & Equipment | CA$424.92K | CA$456.25K | CA$695.48K | CA$589.07K | CA$315.34K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CA$4.46 Million | CA$25.55 Million | CA$14.51 Million | CA$11.67 Million | CA$23.12 Million |
| Total Current Liabilities | CA$4.46 Million | CA$25.55 Million | CA$4.14 Million | CA$2.27 Million | CA$22.54 Million |
| Long-term Debt | — | CA$0.00 | CA$10.30 Million | CA$9.26 Million | — |
| Net Debt | CA$-33.03 Million | CA$-11.72 Million | CA$-14.19 Million | CA$-11.40 Million | CA$12.37 Million |
| Total Stockholder Equity | CA$33.40 Million | CA$2.22 Million | CA$12.86 Million | CA$20.39 Million | CA$-21.21 Million |
| Retained Earnings | CA$-131.00 Million | CA$-105.50 Million | CA$-97.45 Million | CA$-74.19 Million | CA$-51.20 Million |
Eupraxia Pharmaceuticals Inc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Eupraxia Pharmaceuticals Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | CA$-29.99 Million | CA$-27.92 Million | CA$-18.78 Million | CA$-14.64 Million | CA$-403.93K |
| Capital Expenditures | CA$104.23K | CA$73.38K | CA$308.37K | CA$431.67K | CA$431.67K |
| Free Cash Flow | CA$-30.10 Million | CA$-28.02 Million | CA$-19.08 Million | CA$-15.07 Million | CA$-403.93K |
| Investing Cash Flow | CA$-75.16K | CA$-99.03K | CA$8.70 Million | CA$-14.45 Million | CA$24.62K |
| Financing Cash Flow | CA$45.78 Million | CA$27.84 Million | CA$13.52 Million | CA$49.92 Million | CA$-626.64K |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | CA$3.22 Million | CA$1.41 Million | CA$1.43 Million | CA$4.21 Million | CA$228.68K |
| Depreciation | CA$235.25K | CA$155.53K | CA$193.27K | CA$111.53K | CA$116.81K |
| Change in Cash | CA$13.76 Million | CA$1.08 Million | CA$3.84 Million | CA$20.74 Million | CA$-1.01 Million |
Eupraxia Pharmaceuticals Inc Earnings History — EPS Actual vs. Analyst Estimates
Track Eupraxia Pharmaceuticals Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 19, 2026 | — | -0.14 | — |
| Nov 04, 2025 | -0.27 | -0.27 | +0.00% |
| Aug 12, 2025 | -0.36 | -0.25 | -44.00% |
| May 06, 2025 | -0.29 | -0.23 | -26.09% |
| Mar 20, 2025 | -0.28 | -0.16 | -75.00% |
| Nov 07, 2024 | -0.24 | -0.18 | -33.33% |
| Aug 07, 2024 | -0.23 | -0.23 | +0.00% |
| May 08, 2024 | -0.29 | -0.23 | -26.09% |